Overview

All Sanguine study protocols and their resulting samples, which include all Sanguine at-home and apheresis collection programs, are conducted under an Institutional Review Board (IRB). Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant.

Sanguine’s human peripheral blood mononuclear cells (PBMCs) are collected from whole blood or leukopak and expertly isolated within one day to maximize viability and functionality. After cells are isolated, washed, and counted, PBMCs are aliquoted and stored using CryoStor® CS10 freezing media. PBMCs include verified diagnosis for disease state, and donor-reported allergies and infectious disease history.

Well-characterized PBMCs for myelofibrosis research supports studies on bone marrow fibrosis, genetic mutations, and therapeutic development for targeted treatments to manage this myeloproliferative disorder.